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Dendritic cells (DCs) have the unique ability to pick up dead cells carrying antigens in 
tissue and migrate to the lymph nodes where they can cross-present cell-associated 
antigens by MHC class I to CD8+ T cells. There is strong in vivo evidence that the mouse 
XCR1+ DCs subset acts as a key player in this process. The intracellular processes 
underlying cross-presentation remain controversial and several pathways have been 
proposed. Indeed, a wide number of studies have addressed the cellular process of 
cross-presentation in vitro using a variety of sources of antigen and antigen-presenting 
cells. Here, we review the in vivo and in vitro evidence supporting the current mecha-
nistic models and disscuss their physiological relevance to the cross-presentation of 
cell-associated antigens by DCs subsets.
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Cross-presentation is the process by which exogenous antigens captured by phagocytic antigen-
presenting cells are processed and presented onto MHC-I molecules (1, 2). Early evidence supports 
the notion that cell-associated antigens are a physiological substrate for cross-presentation. Indeed, 
cross-presentation was discovered in the context of CD8+ T cell responses to grafts: Bevan et al. dem-
onstrated that engraftment of H-2b cells primes H-2dxb F1 mice for a cytotoxic CD8+ T cell response 
against minor histocompatibility antigens restricted by H-2d (1–3). Therefore, minor histocompat-
ibility cellular antigens from the grafted cells are “cross-presented” by recipient antigen-presenting 
cells to CD8+ T cells, a process termed cross-priming because it is associated with productive CD8+  
T cell activation (cf below). Later on, these findings were translated to tumor antigens as it was 
shown that MHC restriction elements were not required on the tumors to cross-prime tumor-specific 
CD8+ T cells (4, 5). Importantly, cross-priming antigen-presenting cells were found to originate 
in the bone marrow (4–6). The immunological outcome of cross-presentation depends on the 
DC activation state. Cross-priming is achieved by cross-presenting DCs that have received proper 
conditioning by pattern recognition receptor ligation or helper CD4+ T cells (7). By contrast, cross-
presenting “steady-state” DCs mediate the functional inactivation of CD8+ T cells, a process termed 
cross-tolerization (8–10). Self-antigens like the one expressed in pancreatic β-cells, for example, 
were shown to enter the cross-presentation pathway constitutively for a tolerogenic outcome (8, 9). 
Therefore, cross-presentation might participate in the maintenance of peripheral tolerance to tissue-
specific antigens (11). Also, cross-presentation of thymic epithelium self-antigens by bone marrow-
derived cells can participate in the negative selection of auto-reactive CD8+ T cells (12). Importantly, 
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cross-presentation might be mobilized to cross-prime CD8+ T cell 
responses specific to cell-associated viral antigens (4, 6, 13, 14). 
Heath and Carbone have proposed that the cross-presentation is 
an evolutionary response to evasion mechanisms associated with 
the direct infection of DCs by viruses (e.g., the inhibition of direct 
presentation or migratory behavior) (7). This view is supported 
by recent evidence that DCs can perform cross-presentation dur-
ing infection without being infected (15). In all these situations 
(grafts, tumors, viral antigens), antigens are associated with cells 
reach the endocytic pathway of DCs where they gain access to 
the cross-presentation pathway for MHC-I presentation. In vitro, 
pioneer work from Bellone et al. (16) and Albert et al. (13) showed 
that the engulfment of dead cells by murine macrophages (16) or 
human monocyte-derived DCs (moDCs) (13) support the cross-
presentation of cell-associated antigens by MHC-I. Quantitative 
studies demonstrated that association of protein antigen to dying 
cells considerably lowered the amount of antigen required for effi-
cient cross-presentation in vivo (17). In vivo, cross-presentation is 
biased toward highly expressed cellular antigens and favored by 
cellular destruction (18), including cellular destruction dependent 
on cytotoxic CD8+ lymphocytes (18) or NK cells (19). Although 
other mechanisms might exist [nibbling, cytotoxicity by DCs 
(20–22)] these findings support the view that the phagocytosis 
of dead cells by DCs is an efficient mechanism underpinning the 
acquisition of antigens by cross-presenting APCs. Proteins, as 
opposed to proteasomal products (i.e., peptides), constitute the 
source of cell-associated antigens entering the cross-presentation 
pathway (23). Stable membrane proteins (24), in particular, are 
better cross-presented than soluble, short-lived cytosolic proteins 
or epitopes within signal peptides (25, 26). In summary, there is 
extensive in vivo evidence acquired in mouse models, and in vitro 
with human cells, supporting the relevance of cross-presentation 
by MHC-I for CD8+ T cell responses to cell-associated antigens. 
Here, we will review the current evidence identifying dendritic 
cells (DCs) as major players in the cross-presentation of cell-
associated antigens and the mechanistic models that have been 
proposed to explain this phenomenon.
Mouse and Human DC Subsets
Dendritic cells are classified as conventional DCs (cDCs) or plas-
macytoid DCs (pDCs). cDCs represent a heterogeneous set of cells 
found in lymphoid and non-lymphoid tissues that: (i) pick-up and 
process antigens by MHC class I and class II molecules, (ii) acti-
vate naive CD4+ and CD8+ T cells (27–31), (iii) express a specific 
gene signature including the lineage-specific Zbtb46 transcription 
factor (30, 32), (iv) rely on Flt3 receptor tyrosine kinase and its 
ligand for their development (33, 34), and (v) migrate toward T 
cell zones of lymphoid organs by using the chemokine receptor 
CCR7 (35, 36). In both mice and humans, cDCs can be classified 
into two subtypes, the XCR1+ DCs and the XCR1− DCs (“cDC1” 
and “cDC2,” respectively, according to a recent nomenclature 
proposition)(37–39). In mice, the αE integrin CD103 is expressed 
on XCR1+ DCs with the notable exception of the gut where it is 
also expressed on a subset of XCR1− DCs ontogenically distinct 
from cDC1 (40). Also, lymphoid organ-resident XCR1+ cDC1s 
express high levels of CD8α (40). cDC1s express some levels of the 
langerin protein also found in epidermal Langerhans cells (LCs) 
(41–43). Based on these findings, Langerin-DTR mice have been 
largely used as a model of DT-inducible conditional ablation of 
cDC1s (44–46). Overall, mouse cDC1s from various organs lym-
phoid or non-lymphoid share some common transcriptional pro-
grams and genetic requirements (e.g., Id2, IRF8, Batf3) (36, 40). 
In humans, XCR1+ cDC1s express BDCA3, while XCR1− cDC2s 
express BDCA1/CD1c (37, 39, 47–49). Both murine and human 
cDC1s share a common transcriptional program characterized by 
high levels of TLR3, Clec9a/DNGR1 C-type lectin, and the IRF8 
transcription factor (37, 39, 47–49). In vivo evidence obtained in 
Batf3−/− mice (50) and in vitro silencing studies in human CD34+ 
progenitors identified Batf3 as a transcription factor relevant for 
cDC1 development in both species (51). Conversely, mouse and 
human cDC2s express high levels of IRF4 and TLR7 [mouse (52)] 
or TLR8 [humans (39, 53–56)]. Whereas IRF4 is required for the 
development of cDC2 in mice (57), it is not known if this holds 
true for human cDC2s. IRF4 is a master regulator of antigen pres-
entation by major histocompatibility complex class II (MHC-II) 
through the induction of CIITA, the master transcription factor 
controlling the expression of MHC-II genes and accessory 
proteins (Ii, H-2DM) (58). Both cDC1 and cDC2 subsets are 
hematopoietic cells that develop from DC-committed, common 
DC precursors (CDPs) identified both in mice (59, 60) and more 
recently in humans (61). CDPs arise from common progenitors 
for DCs and monocytes (61, 62) and give rise to circulating pre-
cursors called pre-cDCS (63, 64). Finally, fate mapping studies 
(65, 66) and bar-coding of multipotent progenitors (67) identify 
cDCs as a bona fide hematopoietic lineage distinct from other 
mononuclear phagocytes and the lymphoid lineage.
Discrepancies between developmental abnormalities observed 
in cDC subsets in IRF8 mutant mice (57, 68, 69) and IRF8 mutant 
patients cast some doubt upon the actual level of orthology 
between human and mouse subsets. Indeed, Irf8−/− mice are fully 
deficient in cDC1 (and pDCs and monocytes) but not cDC2. 
IRF8R294C hypomorphic mutant mice (69) are also deficient in 
cDC1 (but not pDCs). By contrast, human genetic studies showed 
that patients with the IRF8K108E mutation are deficient in both 
cDC1 and cDC2 (and monocytes), whereas a patient with the 
IRF8T80E mutation selectively lacked circulating BDCA1+ cDC2 
(70). Therefore, the conservation of developmental requirements 
between mouse cDC1 and human cDC1, if any, remains to be 
fully understood.
Plasmacytoid DCs represent a heterogeneous group of cells 
expressing specific markers in mice (PDCA-1, SiglecH) and 
humans (BDCA2/CD303, CD123). Mouse and human pDCs 
exhibit a high level of conservation in their gene expression pat-
tern (71). Both rely on the Tcf4/E2-2 bHLH transcription factor 
(72) [and its Spi-B target gene (73, 74)] and can be generated from 
CDPs and other Flt3+ progenitors (61, 75–77).
Finally, moDCs represent a heterogeneous set of cells that are 
different from cDCs because: (i) they originate from monocytes 
and not pre-cDCs, (ii) they are absent at the steady state, (iii) 
in vivo, they rely on Ccr2-dependent egress of the bone marrow 
(78, 79). In vivo, moDCs arise in various inflammatory conditions 
triggered by exposure to foreign objects such as recall antigens 
(mBSA) (80), LPS (81), or during infections such as Listeria 
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monocytogenes (82, 83). Listeria-induced iNOS+ moDCs are 
independent of GM-CSF (83) while mBSA-dependent moDCs 
rely on GM-CSF (80). In vitro generated GM-CSF-derived DCs 
(84) are a popular source of DCs for cellular studies even if they 
are developmentally distinct from cDCs (85).
In vivo evidence for the Role of Murine 
cDC1 in Cross-Presentation
If cross-presentation can be obtained using multiple antigen-
presenting cells in vitro, including moDCs or macrophages for 
example, the available in vivo evidence suggests that cross-presen-
tation is mostly performed by the mouse CD8+/CD103+ subset of 
cDCs (cDC1s). Evidence supporting this paradigm was obtained 
by analyzing ex vivo MHC-I peptide complexes on spleen DCs 
sorted from mice that had previously received an intravenous 
injection of OVA antigen-loaded cells (86). CD8α+CD11b− cDC1 
but not the CD8α−CD11b+ cDC2 were found to perform cross-
presentation. cDC1s were also involved in the constitutive cross-
presentation of a pancreatic model antigen (RIP-OVA) (8, 9, 87). 
Also, lung cDC1s pick up intranasally delivered soluble antigens 
or cell-associated antigens, transport them to mediastinal lymph 
nodes, and perform cross-presentation (88, 89).
Which DC subsets perform cross-presentation during viral 
infections? Allan et al. have shown that upon HSV skin infection, 
skin migratory DCs, but not radio-resistant LCs, were responsible 
for the early transport of antigens to the lymph node, where anti-
gen is transferred to lymphoid resident CD8+ cDC1s, mediating 
CD8+ T cell priming (90, 91). Similar findings advocating a major 
role for lymphoid organ-resident cDC1s cross-presenting cell-
associated antigens have been reported in multiple infection sys-
tems (92). Later on, this idea was challenged by Bedoui et al. who 
addressed the efficiency of ex vivo presentation by the different 
DC subsets after 5 days of infection with HSV-1 (93). The isola-
tion of DCs from axillary lymph nodes draining a site of second-
ary infection (associated with viral recrudescence) demonstrated 
that the CD103+ migratory cDC1s had a predominant role in 
the presentation of viral antigens to specific CD8+ T cells ex vivo 
(93). However, ex vivo T cell activation in this system does not 
discriminate between cross-presentation and direct presentation. 
Bedoui et al. obtained formal evidence of the role of migratory 
cDC1 in cross-presentation using a membrane-associated form 
of ovalbumin (OVA) expressed in epidermal keratinocytes (93). 
Finally, selective depletion of migrating langerin+ cDC1s (but not 
LCs) was shown to be required for the constitutive cross-presen-
tation of keratinocyte antigens formally demonstrating the key 
role of migratory cDC1s in cross-presentation of cell-associated 
antigens from the periphery (46).
Upon lung Influenza virus infection, there is an increase in 
the population of langerin+CD103+CD11b−CD11c+ cDC1s in the 
mediastinal lymph node (94). The depletion of this population of 
cells in Langerin-DTR mice leads to a decrease in the clearance of 
Influenza virus together with a significant decrease in CD8+ cyto-
toxic responses (94). Importantly, a subsequent study showed that 
among all the DC subsets in mice infected with a recombinant 
influenza virus, only the lung CD103+ cDC1s carried antigens 
from a recombinant Influenza virus expressing a green fluores-
cent protein (GFP) fused to NS1, a non-structural protein of the 
virus, to the draining lymph node (15). Importantly, CD103+ 
cDC1s carrying GFP+ material derived from infected cells were 
not infected. Therefore, this study elegantly demonstrated that 
cross-priming DCs mediate CCR7-dependent delivery of cell-
associated viral antigen to draining lymph nodes without being 
infected (15). Also, depletion of cDC1s in Batf3−/− mice abrogates 
CD8+ T cell responses to West Nile virus, but the contribution 
of cross-presentation in this process is not formally established 
(50). Altogether, the migratory CD103+ cDC1s have emerged as 
a pivotal DC population in the control of CD8+ T cell responses, 
especially in the context of viral infections.
CD103+ DCs might also have a role in other types of infec-
tions. Splenic CD8+ cDC1s isolated from the spleens of mice 
infected with Plasmodium berghei ANKA were much more 
efficient in cross-presenting malaria antigens than cDC2s (95). 
As a consequence, depletion of cDC1s in Langerin-DTR mice 
(96) or Clec9a-DTR (97) mice abrogates immuno-pathological 
CD8+ T cell responses associated with P. berghei ANKA infection. 
In the case of malaria infection, cross-presentation is absolutely 
required for CD8+ T cell responses, since parasites invade only 
red blood cells devoid of MHC class I(98).
Are Other DCs Types involved in  
Cross-Presentation In vivo?
Monocyte-derived DCs generated in inflammatory conditions 
in vivo are capable of cross-presenting, to some extent, soluble 
OVA or OVA expressed by E.coli (81, 99). However, it is unclear 
if this mode of cross-presentation is relevant for the induction 
of CD8+ T cells in  vivo, in particular against cell-associated 
antigens. Immunization based on skin inflammation was shown 
to involve CCR6-dependent inflammatory cells that cross-
present to CD8+ T cells (100). Also, moDCs might support the 
expansion of antigen-experienced CD8+ T cells in the periphery 
(101). If these studies (100, 101) implicate moDCs in antigen 
presentation to CD8+ T cells, it remains unknown if moDCs 
can perform the cross-presentation of cell-associated antigens 
in  vivo. Interestingly, it has been shown that circulating CD14 
monocytes of chronic HBV patients contain big amounts of viral 
antigen that are mobilized to elicit T cell proliferation when they 
are differentiated into moDCs (102).
In spite of the lack of cross-presenting activity in steady-
state conditions, one study showed that upon stimulation with 
TLR7 agonists in vivo or in vitro, the capacity of splenic pDCs 
to cross-present antigens was increased suggesting that they 
might contribute to cross-presentation in vivo (103). However, 
depletion of pDCs by the injection of 120G8 antibodies does 
not affect CD8+ CTL responses to Influenza (94). Likewise, the 
administration of OVA coupled to a PDCA-1 antibody which 
would direct the antigens to the pDCs does not elicit CD8+ 
responses in the absence of cDCs (104). Taken together, there 
is little evidence for a role of pDCs in cross-presentation in vivo 
despite the recent evidence of their contribution to some CD8+ 
anti-viral responses, through the orchestration of innate immune 
responses (105, 106).
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Are Human cDC1 Specialized in  
Cross-Presentation?
There is currently some controversy on whether human cDC1s 
are endowed with a better cross-presenting ability than cDC2s. 
Many reports have analyzed the cross-presentation of antigens 
associated with necrotic cells to antigen-specific CD8+ T cell 
clones in  vitro. Using HIV-infected necrotic cells, Crozat et  al. 
reported that cDC1s are more efficient at stimulating a CD8+ T cell 
line specific for the HIV protein pol (37). Jongbloed et al. analyzed 
cross-presentation of HCMV-infected necrotic fibroblast to pp65-
specific CD8+ T cells and reported similar findings using DCs 
purified from blood (48). Finally, Bachem et al. also concluded the 
superiority of blood cDC1s in cross-presenting cell-associated 
antigens from freeze-thawed transfectants expressing the pp65 
HCMV protein (47). By analyzing the tonsil-derived cDC1s, 
cDC2s, and pDCs, Segura et al. concluded that both cDC1s and 
cDC2s have a similar ability to cross-present cell-associated 
antigens that is not shared by pDCs (107, 108). In contrast, Tel 
et al. showed that pDCs can cross-present receptor-targeted Ags 
to cytotoxic T lymphocytes so efficiently as cDC1 (109).
Finally, Haniffa et al. have identified a skin CD141+ cDC1 subset 
capable of cross-presenting a hepatitis B surface antigen (HBsAg) 
to specific CD8+ T cell clones upon stimulation with TLR3 agonists 
and exposure to a cytokine maturation cocktail (110).
Some experiments, however, support the idea that cDC1s 
might be endowed with a better ability to cross-present exog-
enous antigens independently of dead cell engulfment. Indeed, 
two studies have reported that cDC1s have a better ability to 
cross-present soluble proteins to antigen-specific CD8+ T cell 
clones (47, 48). This result is in stark contrast to the data of Segura 
et al. who did not identify a detectable cross-presentation activity 
for a long peptide in circulating, non-activated cDC1s and cDC2s 
(107). Both cDC1s and cDC2s from the tonsil, however, were 
found to be able to cross-present soluble antigens (long peptides 
and protein antigens) efficiently, together with pDCs (108). Also, 
pDCs have been reported to cross-present vaccinal lipopeptides 
and HIV-1 antigens from apoptotic cells to specific CD8+ T 
lymphocytes as efficiently as cDC2 (111).
Dendritic cells derived from CD34+ hematopoietic progeni-
tors are increasingly used as a convenient model for the study of 
cross-presentation by DCs. Pioneering work by Poulin et  al. 
has characterized the cDC1 progeny of CD34+ progenitors dif-
ferentiated in a Flt3L/SCF/GMCSF/IL4 cytokine cocktail (49). 
Poulin et al. have shown that cDC1-like TLR3+Clec9a+ cells were 
capable of cross-presenting Melan-A long peptide upon polyI:C 
activation (49). Using a similar culture system, by systematic 
comparison of cDC1s and cDC2s, Balan et al. have found that 
XCR1+TLR3+Clec9a+ cDC1s have a better ability to cross-present 
cell-associated HCMV pp65 associated with K562 cells than 
BDCA1/CD1c+ cDC2s (112). These data contrast with the study 
of Proietto et  al. showed that both cDC1 and cDC2 obtained 
in Flt3L/TPO cocktail do not display differences in the cross-
presentation capability of an Influenza virus protein to a specific 
CD8+ T cell (113). Finally, Segura and Kletchevksy have firmly 
established the cross-presentation abilities of CD1a+ DCs derived 
from CD34+ cord blood progenitors cultivated in GMCSF/Flt3L/
TNF-α (108, 114). The developmental and phenotypic relation-
ship of these cells that share a lot of features with epidermal 
LCs (114) raise some interesting questions on the regulation of 
cross-presentation in vivo in the human system. Supporting this 
idea, another group showed that human LCs were, at steady state, 
more efficient than dermal DCs in cross-presenting long peptides 
to CD8+ T cells, (115).
is the Ability to engulf Dead Cells 
Associated with a Specific DC Subset?
Den Haan et al. first identified the mouse DC1 subset as the main 
phagocytic subset involved in the phagocytic uptake of dead cells 
in situ (86). Iyoda et al. later extended these findings in the context 
of NK-mediated killing of allogeneic targets (19). More recently, 
Desch et al. have identified that mouse lung cDC1s have a specific 
ability to pick up intranasally delivered dead cells (89).
In summary, there is a general agreement on the fact that murine 
cDC1s have a higher ability to pick up dead cells as compared 
to cDC2s. In humans, however, the situation is not that simple. 
Jongbloed et al. found that the superiority of DC1s (as compared 
to cDC2s) has not been attributed to a specific ability to pick up 
material from dead cells (48). By contrast, Segura et  al. found 
that both cDC1s and cDC2s (but not pDCs) were found capable 
of engulfing dead cell material from fluorescently necrotic cells 
(107, 108). Despite their ability to perform cross-presentation 
of long peptides and proteins with the same efficiency as cDC1s 
or cDC2s, pDCs are poorly able to engulf material from dead 
cells and to cross-present cell-associated antigens (107, 108). In 
summary, unlike in the mouse system, both human cDC1 and 
cDC2 seem to be able to pick up necrotic dead cell material with 
no obvious differences in efficiency.
what are the Receptors implicated in the Uptake 
of Dead Cells by cDCs?
The mechanisms of dead cell engulfment by macrophages are 
complex and involve multiple receptors that have cooperative or 
redundant roles (116). Phosphatidylserine exposure associated 
with cell death engages directly macrophage receptors (e.g., TIM4, 
CD36) and also leads to the deposition of multiple opsonins (e.g., 
MFGE8, Gas6, protein S) engaging various macrophage receptors 
(e.g., alphaV integrins or MerTK/Axl tyrosine kinases). Dead cell 
uptake in macrophages requires a coordinated process of direct 
recognition of “eat-me” signals and the subsequent activation of 
intracellular signaling pathways. For example, TIM4 receptors 
mediate the uptake of dead cells to the macrophage plasma mem-
brane by direct recognition of phosphatidylserine (117), whereas 
tyrosine kinases like MerTK triggers a signaling cascade that leads 
to an actin-remodeling process promoting engulfment (118). 
Initial work by Albert et al. showed that the alphaVbeta5 (αVβ5) 
integrin and CD36 scavenger receptor play an important role in 
dead cell uptake by human moDCs (119). However, murine DC1 
spleen cells from Cd36−/− and β3β5−/− mice are not deficient in the 
uptake of dead cells and cross-presentation (120, 121). By con-
trast, neutralizing antibodies to αV integrins and CD36 inhibits 
efferocytosis by human splenic CD141+ cDC1s (122). Therefore, 
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the involvement of CD36 and aV integrins in dead cell uptake 
by DCs remains controversial, as it is not clear if DCs and mac-
rophages share similar mechanisms to perform efferocytosis. In 
this sense, evidence for specific cell-type efferocytic mechanisms 
are reinforced by a study showing that the inhibition of phos-
phatidylserine recognition in vivo impairs macrophage dead cell 
uptake, but promotes efferocytosis by spleen CD8α+ DCs (123).
Mouse cDC1s express DEC205 (124) and DNGR1/Clec9a 
(125) lectins and both have the ability to bind to dead cells. 
Analysis of DEC205−/− (19) failed to reveal any default in the 
internalization of dead cells by cDC1s. Clec9a/DNGR1, in par-
ticular, has been shown to bind filamentous actin (126–128) and 
is also selectively expressed by mouse and human cDC1s (49, 51, 
129, 130). Surprisingly, in spite of its ability to bind to necrotic 
cells by engaging filamentous actin (126–128), Clec9a/DNGR1 
is not controlling the uptake of dead cells by the cDC1s DCs 
(125, 129, 130).
More recently, TIM3 has been involved in the phagocytosis of 
apoptotic cells by the mouse DCs (131). Anti-TIM3 antibodies 
inhibit efferocytosis by mouse cDC1s in vitro and in vivo, and par-
tially decrease cross-presentation as well (122, 131). Although the 
role of TIM3 in cross-presentation by human cDCs has not been 
assessed, a recent paper has shown that TIM3 is highly expressed 
in tumor-associated cDCs in humans (132). Another scavenger 
receptor, SCARF-1, has also been involved in efferocytosis in 
mouse cDC1 (133) although the administration of neutralizing 
anti-SCARF-1 antibodies does not have any effect on the effero-
cytosis by human spleen cDC1 (122). Whether SCARF-1 plays 
a role in cross-presentation has not been established. Finally, 
the Axl tyrosine kinase has also been involved in efferocytosis 
by DCs (122). Axl would mediate the recognition of opsonized 
dead cells while RANBP9 mediates its interaction with the LRP1 
phagocytic receptor (122). Inactivation of either member of this 
complex leads to pronounced reduction in dead cell uptake by 
mouse cDC1 with the subsequent decrease in cross-presentation 
of cell-associated antigens. Importantly, antibody blockade indi-
cates that Axl and Lrp1 are also needed for the uptake of dead cells 
by human splenic cDC1 (122).
In summary, mouse and human cDC subsets might recruit 
overlapping as well as distinct set of receptors to mediate the 
engulfment of dead cells. Whether the nature of cell death might 
influence these choices and the cellular consequences for cross-
presentation of cell-associated antigens remains to be analyzed.
Does Antigen Targeting to endocytic 
Receptors Trigger Cross-Presentation in 
all Subsets?
If murine cDC1s have a clear advantage in dead cell uptake as 
compared to cDC2s, it is conceivable that additional intracellular 
processes might also contribute to efficient cross-presentation 
of cell-associated antigens. In support of this notion, Schnorrer 
et  al. have shown that phagocytic cDC1 cross-presents OVA 
more efficiently than cDC2, even at normalized amounts of 
phagocytozed antigen (134). Is it possible to overcome these 
subset-specific differences in cross-presentation efficiency by 
increasing the efficiency of antigen loading by targeting endocytic 
receptors? For example, experiments from the Cresswell labora-
tory have demonstrated that 293T cells rendered phagocytic by 
enforced expression of FcgRIIA are capable of cross-presenting 
antibody-targeted antigens (135). Therefore, it is tempting to 
conclude that every cell is able to perform cross-presentation 
provided that exogenous antigens are delivered efficiently inside 
the endocytic pathway. Complex particles like bacteria (136) 
or yeast (137), engaging multiple receptors and triggering cell 
activation, overcome the superiority of mouse cDC1 to perform 
cross-presentation, at least in vitro (138). However, by carefully 
measuring the rates of antigen uptake, Kamphorst et al. were able 
to demonstrate the superiority of cross presentation efficiency by 
cDCs (cDC1 or cDC2) over GMCSF-induced moDCs regardless 
of the route of antigen capture (receptor-mediated endocytosis, 
macro-pinocytosis or phagocytosis) (139). Therefore, cDCs 
appear to be endowed with a kind of capability to perform 
cross-presentation, irrespectively of cDC1/cDC2 subset, more 
efficiently than other phagocytic cell types even if antigen is 
delivered through receptor-mediated endocytosis (139).
Elegant experiments from the Nussenzweig laboratory 
have established that targeting of exogenous antigen to mouse 
DEC205 via antigen-antibody conjugates leads to efficient 
antigen cross-presentation in cDC1 cells that selectively express 
DEC205 (10, 140). When targeted to cDC2s, the same antigen 
is not cross-presented efficiently (140). Transgenic expression of 
human DEC205 in both cDC1 and cDC2 cells using the CD11c 
promoter and antibody-mediated targeting was instrumental in 
showing that (i) efficient capture of OVA by huDEC205 leads 
to efficient cross-presentation by both cDC1 and cDC2 and 
(ii) in the same cells (cDC2), huDEC205 leads to better cross-
presentation than DCIR2 targeting (139). Unlike mouse DEC205, 
human DEC205 is expressed in both human cDC1s and cDC2s. 
Efficient cross-presentation is achieved in both cDC1s and cDC2s 
when antigen is targeted to CD40 or CD11c but not DEC205 
despite the ability of DEC205 to trigger efficient internalization 
of antibody-antigen conjugates in both subsets (141, 142). In 
conclusion, the level of subset specificity achieved by receptor 
targeting in cross-presentation is fully dependent on the endo-
cytic receptor used (139, 141, 142). Overall, cDC2 are largely able 
to perform efficient cross-presentation upon targeting of antigen 
to some specific receptors (139, 141, 142). These findings are 
important for the design of vaccines (143), but one may wonder 
if receptor-dependent cross-presentation by cDC2s is physi-
ologically relevant. In physiological settings, antibody-mediated 
uptake by FcγR might significantly boost the cross-presentation 
of antigens by cDC2s. This was shown in vitro, for example, with 
the cDC2-like D1 cell line or moDCs (144) and in  vivo after 
the injection of immune complexes (145). This mode of uptake 
might serve the cross-presentation of cell-associated antigens 
when antibodies raised against cell surface antigens mediate cel-
lular engulfment (146). This situation might be important in the 
context of immune responses to viral infections when antibodies 
might bind viral glycoproteins at the surface of infected cells and 
promote the cross-presentation of cell-associated viral antigens. 
Also, antibodies against model membrane antigens expressed in 
pancreatic β cells activate its cross-presentation in vivo (147).
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Cytosolic versus vacuolar  
Cross-Presentation
What are the intracellular mechanisms of antigen processing 
and presentation underpinning cross-presentation? Currently, 
there are two main models explaining how antigens can be 
processed to load MHC-I receptors for cross-presentation. These 
models are referred to as “cytosolic” and “vacuolar” pathways. 
In the cytosolic model, antigens are released from the lumen 
of phagocytic compartments to the cytoplasm where they are 
further processed into short peptides by the proteasome (148). 
The transporters associated with antigen processing (TAP1/
TAP2) translocate proteasomal peptide products to the lumen 
of the MHC class I loading compartment where they gain access 
to the MHC-I loading machinery including tapasin, ERp57, and 
calreticulin (148). The first evidence supporting the so-called 
cytosolic model came from studies using antigen associated with 
beads and macrophages as the source of antigen-presenting cells 
(149). Importantly, this study demonstrates the existence of a 
phagosome-to-cytosol transport pathway. Indeed, coupling of 
the gelsolin protein toxin to beads was sufficient to mediate its 
cytosolic delivery probed functionally by translational inhibi-
tion (149). Cross-presentation of phagocytosed antigen was 
inhibited by proteasome inhibitors, genetic inactivation of the 
TAP1/TAP2 transporters and Golgi disruption by brefeldin A, 
a Golgi-disrupting agent (149). These experiments constitute 
the foundation of the cytosolic model of cross-presentation in 
which phagocytosed antigens are processed within the cytosol 
by the proteasome in a similar way to endogenous antigens. 
TAP requirement for cross-presentation has also been identified 
for cell-associated antigens in vivo (6, 150). Favereau et al. have 
shown that the cross-presentation of cell-associated antigens by 
human moDCs uses the cytosolic pathway (151). However, the 
criterion of TAP requirement has to be considered with some 
caution since genetic inactivation of TAP1 or TAP2 destabillizes 
MHC-I and impairs its transport at the cell surface (152). As 
a consequence, low-temperature incubations, which restore the 
levels of MHC-I at the plasma membrane in TAP−/− cells, can 
rescue the cross-presentation of phagocytosed antigens (153, 
154). In addition to TAP requirement, experimental evidence 
of the cytosolic pathway relies on pharmacological proteasome 
inhibition.
In the vacuolar pathway, extracellular antigens are internal-
ized and degraded in the endosomal compartments by lysosomal 
enzymes, and the resulting peptides are loaded onto MHC-I 
molecules within the endosomal compartment by a process akin 
to MHC-II presentation. Pioneering work from the Harding 
laboratory showed that cross-presentation can be achieved in 
macrophages in the absence of functional TAP transporters 
and in a way that is insensitive to pharmacological inhibition 
of the proteasome (155). Later on, TAP-independent cross-
presentation was shown to involve cathepsin S (156). It is gen-
erally admitted that the vacuolar form of cross-presentation is 
associated with high levels of antigen delivered in the endocytic 
pathway. Whether this might be a physiological way to handle 
cellular antigens, or perhaps the most abundant of them, remains 
to be established.
Antigen Retention in the endocytic 
Pathway of Cross-Presenting cDCs
There is a wealth of evidence supporting the notion that limited 
endo-lysosomal proteolysis of engulfed antigens promotes their 
efficient cross-presentation by cDCs. Overall, limited endo-
lysosomal proteolysis is associated with the DC lineage (157, 158). 
An elegant study by Delamarre et al. showed that GM-CSF DCs, 
splenic DCs and DCs from lymphoid organs expressed lower lev-
els of lysosomal proteases than in vitro differentiated macrophages, 
splenic, lymphoid, and peritoneal macrophages. This correlates 
with a decrease in the capacity of DCs to degrade soluble proteins 
in vitro and in vivo (158). These findings were extended to human 
DCs derived from CD34+ hematopoietic progenitor cells or isolated 
from peripheral blood, which, in comparison with macrophages, 
are also protease poor (159). Overall, human cDCs express less 
cathepsin B, L, and S than moDCs, and both murine and human 
cDC2s express slightly more proteases than cDC1s (140, 142).
In addition to their low content in proteases, DCs also limit the 
activity of acid-dependent lysosomal proteases by maintaining a 
relatively alkaline endocytic pathway. Pharmacological inhibition 
of endocytic acidification by treatment with cloroquine, ammo-
nium chloride, or protease inhibitors boosts cross-presentation 
of endocytosed proteins in human moDCs or cDC2 (141, 160, 
161). The relatively high endo/phagosomal pH of DCs is mainly 
explained by two factors.
First, in immature DCs an important fraction of the cytosolic 
subunits of the vacuolar ATPase (V1 sector) appears dissociated 
from the trans-membrane V0 sector. As a proper assembly of both 
subunits is needed for the function of the V-ATPase, the higher pH 
can be partially explained by a deficient transport of protons to the 
lumen of the lysosome (162). Activation of DC maturation in vitro 
promotes the assembly of the complex and its role in luminal acidi-
fication (162). Interestingly, the phosphatidylinositol 3-kinase/
mTOR pathway has recently been identified as an upstream 
regulator of the V-ATPase assembly during DC activation (163).
Second, the NADPH oxidase regulates phagosomal acidifica-
tion in murine and human GM-CSF moDCs and CD8α+ cDC1s 
(164–166). The NOX2 complex is recruited to the phagosomal 
membrane and produces reactive oxygen species (ROS) that 
activates proton consumption and induces lumenal alkalinization 
(164, 166). As a consequence, both mice and human DCs deficient 
in functional NADPH oxidase have reduced cross-presentation 
(164–166). Recruitment of the Rac2 GTPase to phagosomes would 
support cDC1 NADPH oxidase at phagosomal membranes (166). 
The relevance of the Rac2/NAPDH oxidase complex on the cross-
presentation of cell-associated antigens in vivo remains to be tested.
Another level of regulation of the phagocytic pathway involves 
the endoplasmic reticulum (ER)-resident 47  kDa interferon-
inducible GTPase, Irgm3, and its Perlipin2/Adrp partner (167). 
Irgm3 is expressed in both mouse cDC1 and cDC2s subsets and 
further induced upon TLR3 activation (167). Irgm3 associates 
with the ER and lipid bodies (LBs) of DCs where it directly 
interacts with the LB coat protein Perilipin2 (167). The depletion 
of Irgm3 or Perilipin2 decreases the number of LBs at steady state 
and abrogates their induction upon IFNɣ and poly:IC treatments, 
whereas Irgm3 over-expression does the contrary. Importantly, 
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the splenic cDC1s show higher steady-state levels of LBs than 
the cDC2s (167), which can be explained by higher Perilipin2 
levels (53, 140, 167). The reduction of LBs by pharmacological 
treatments or genetic inactivation of Perilipin2 or Irgm3 inhibits 
cross-presentation by mouse cDC1, including the cross-pres-
entation of cell-associated antigens in  vivo (167). Interestingly, 
Irgm3−/− moDCs have an accelerated phagolysosomal maturation 
as compared to their WT counterparts. The mechanisms under-
lying this effect are unknown, but a direct association between 
LB and the phagosomal membranes has been demonstrated in 
moDCs (167) and other cells (168). Interestingly, the NOX2 
complex protein gp91phox controls the recruitment of the cytosolic 
phospholipase A2 (PLA2) and LBs themselves to phagosomes 
(169, 170). An interesting hypothesis is that LBs might provide a 
lipid source for the formation of the NOX2 activator arachidonic 
acid (AA) in a PLA2-dependent manner (171, 172). Therefore, 
it is conceivable that NOX2 and LBs might cooperate to regulate 
oxidative metabolism with consequences for antigen proteolysis 
and, in fine, cross-presentation.
Finally, “antigen retention” early endocytic compartments segre-
gated from the normal progression of endosomes to lysosomes have 
been described in DC lines after macro-pinocytosis or antibody-
mediated uptake of soluble antigens (173, 174). Antigen retention 
compartments might provide a long-term source of antigen for the 
continuous loading of MHC-I receptors (173, 174). Burgdorf and 
Kurts found that mannose receptor targeting, but not fluid phase 
uptake, leads to prolonged antigen accumulation of antigen in anti-
gen retention compartments with slow rates of maturation to lys-
osomes (175–177). This compartment is accessible to TAP and MHC 
class I loading complex upon TLR stimulation (176) (see below). 
Moreover, they can acquire the MHC class I antigen trimming 
enzyme insulin responsive aminopeptidase (IRAP), since mannose 
receptor endosomes partially overlap with the vesicular compart-
ment described by IRAP, an enzyme that interacts with MHC class 
I molecules and performs antigen trimming in endosomes, in a 
model of proteasome-dependent cross-presentation (178). In the 
absence of IRAP, in vivo cross-presentation of antigens targeted to 
mannose receptors is compromised, underlining the functional 
relevance of mannose receptor and IRAP endosomes overlapping 
(178). However, there is a controversy regarding the relevance of 
this pathway for the uptake of OVA by spleen cDCs, specifically 
cDC1 (99, 177, 179). More generally, one might wonder if mannose 
receptor-targeted IRAP+ endosomes are of relevance regarding the 
cross-presentation and routing of cell-associated antigens during 
the engulfment of dead cells, which might be processed in the 
phagosome. In the phagosome, MHC class I ligand production is 
usually the result of a cooperative action of cytosolic proteasome, 
ER-resident trimming aminopeptidases and IRAP (180).
Dendritic cells receptors involved in dead cell uptake or sensing 
might regulate phagosome maturation to promote antigen reten-
tion for cross-presentation. In support of this notion, Sancho et al. 
have shown that Clec9a−/− cDC1s have reduced cross-presentation 
of cell-associated antigen, in vitro and in vivo (125). By contrast, 
Clec9a−/− cDC1s normally cross-present antigen coupled to latex 
beads suggesting a cargo-specific process (125, 181). Ligation 
of danger-associated molecular patterns found in dead cells like 
filamentous actin might act as a regulator of the trafficking of dead 
cells in cDC1s (126, 182). Supporting this notion, DNGR1/Clec9a 
deficiency inhibits the accumulation of Rab5a and Rab11 markers 
to the dead cell phagosome (182). A quantitative analysis of dead 
cell-containing phagosomes has been performed by the Janssen 
laboratory (183, 184). These authors have shown that cell remnants 
captured by murine splenic cDC1s, in particular a CD8α−Clec9a+ 
subset of cDC1s, have a smaller size and a longer persistence (up to 
20 h) as compared to the ones captured by spleen cDC2 (183, 184). 
Interestingly, endocytic compartments carrying dead cell debris 
remains poorly acidified and retain early endocytic markers such 
EEA1 (183, 184). These in vitro data are consistent with the fact 
that cell debris carrying intact GFP from infected cells engulfed 
in the lung could still be found in non-infected, phagocytic cDC1 
having reached lung draining lymph nodes (15). Overall, antigen 
retention by migratory cDCs might enable the coordination of 
antigen presentation/cross-presentation with migration from 
antigen sampling sites (tissues) to the T cell areas of the lymph 
nodes. However, the nature of antigen retention compartments 
and the mechanisms regulating the access of cell-associated anti-
gens to this compartment remains to be addressed in more detail.
The Translocation of Phagosomal 
Antigens inside the Cytosol in cDCs 
Subsets
Initial work from the Watts laboratory identified growth factor-
induced macro-pinocytosis as an efficient, actin-dependent, 
endocytic process leading to the export of captured antigens 
to the cytosol (185). Importantly, immature moDCs and cDCs 
were found to display constitutively active macro-pinocytosis 
mediating the delivery of exogenous antigens to the cytosol for 
cross-presentation (186, 187). Later on, morphological evidence 
of cytosolic access of protein antigens targeted to Fc-receptors and 
soluble dextrans were reported in DCs (188, 189). Importantly, 
antigen transport to the cytosol was found to be specific for DCs 
since it was not observed in macrophages (188).
Is the cytosolic pathway for cross-presentation active in spe-
cific cDCs subsets in vivo? Plamowski et al. have shown in vivo 
that cross-priming against an HY-encoded minor histocompat-
ibility antigen is reduced in mice deficient for some immune-
proteasome subunits (LMP7−/−) (190). This study represents a 
unique in vivo, indirect genetic demonstration of the involvement 
of the cytosolic pathway in the cross-priming of CD8+ T cells 
toward cell-associated antigens. The most compelling in  vivo 
direct evidence of cytosolic export comes from a work in which 
mice were injected with soluble cytochrome c protein. Following 
this treatment, Apaf-1-dependent apoptosis was used as a readout 
of cytochrome c release to the cytosol (191). Lin et al. observed 
a selective depletion of spleen cDC1s (CD8+CD103+) upon 
cytochrome c depletion. These experiments suggest that cDC1s 
might be endowed with a specific ability to release antigen from 
the endocytic pathway inside the cytosol. Do these findings 
translate to humans cDC1s? This is not completely clear. Indeed, 
cross-presentation by human cDC1s is largely blocked by inhibi-
tors of the proteasome supporting the use of soluble antigens in 
the cytosolic pathway (48, 108). Segura et al. have used an elegant 
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β-lactamase-based fluorescent assay to monitor the delivery of 
soluble proteins to the cytosol of DCs (108). Using this assay they 
found that cDC1, cDC2, and pDCs (but not CD14+ macrophages) 
all perform the cytosolic export of endocytosed antigens efficiently 
(108). This elegant assay might selectively visualize early events 
of translocation, before possible destabilization of the enzyme by 
endo-lysosomal proteolysis. Distinct conclusions were obtained 
by Cohn et al. who report that cDC1s, but not cDC2s, do cross-
present antigens when they access late endocytic compartments 
(142). This was exemplified with fusion-defective viruses, Listeria-
encoded antigens from translocation-defective (LLO−) strains 
or DEC205 receptor targeting (142). An interpretation of these 
important findings is that cytosolic cross-presentation could be 
mediated by two pathways: an early endocytic cross-presentation 
pathway which is functional in both cDC1 and cDC2s, and a 
late endocytic pathway more specifically associated with cDC1s 
(141, 142). The later process could imply the existence of specific 
lysosomal mechanisms for efficient antigen export only present in 
the cDC1. Alternatively, lysosomal processing of antigens could 
occur more slowly in the cDC1 allowing their cytosolic export 
before complete lumenal degradation. Further mechanistic stud-
ies are needed to decipher whether the translocation of antigens 
to the cytosol is an active process associated with the endocytic 
membranes of cDCs or a passive process associated with the 
accumulation of non-degraded proteins in endocytic compart-
ments. In support of the latter, experimental inhibition of protein 
degradation leads to improved transport in the cytosol (160, 189).
A Role for endoplasmic  
Reticulum-Associated Degradation in the 
Translocation of Phagocytic Antigens  
into the Cytosol by cDCs
With the existence of a phagosome-to-cytosol pathway being 
well accepted, the mechanisms underlying the translocation of 
antigens across the endocytic membrane are the focus of intense 
investigations. In multiple experimental systems, enzymatically 
active proteins have been found in cytosolic extracts, suggesting 
that the cytosolic translocation might not necessarily involve pro-
tein unfolding. The disruption of endocytic membranes might 
be put forward as a hypothesis. Indeed, experimental osmotic 
disruption of endo-lysosomes is sufficient to trigger cross-
presentation of exogenous antigens (192). However, disruption 
of endo-lysosomal membranes is associated with the induction 
of cell death by lysosomal proteases [e.g., cathepsin (193)]. A 
popular hypothesis explaining the transport of antigens to the 
cytosol involves the access of endocytic antigens to transloca-
tion processes associated with the ER. The active transport of 
ER-associated ill-folded proteins inside the cytosol for protea-
somal degradation (ERAD) in particular has been speculated 
to regulate cross-presentation by MHC-I. The channel protein 
sec61, which has been involved in the export of mis-folded 
proteins to the cytosol as part of the ERAD machinery (194, 195) 
is present in the phagosomal membrane together with other ER 
markers (196–198). More recent studies have shown that the 
ER-resident SNARE sec22b is directly involved in the recruitment 
of ER membranes to the phagosome, possibly favoring the onset 
of ERAD of luminal antigens (199). The specific involvement of 
sec61 in the translocation of peptides to the cytosol has been 
demonstrated in vitro using assays in which the export of radio-
labeled peptides from microsomes was inhibited in the presence 
of the sec61 inhibitor Pseudomonas aeruginosa exotoxin A 
(ExoA) (200). The knockdown of sec61 in the DC2.4 moDCs line 
decreased cross-presentation of soluble OVA supporting that it is 
a role for sec61 in cross-presentation (201). A more recent paper 
has demonstrated that sec61 is recruited to endosomes carrying 
OVA antigen and that such recruitment depends on TRIF signal-
ing. Inhibition of sec61 release from the ER to the endosomes 
using a specific antibody against sec61 fused to an ER retention 
sequence impairs cross-presentation and antigen export to the 
cytosol in DC2.4 and BMDCs (202).
However, the involvement of sec61 in cross-presentation by 
the human DC subsets is still controversial, as it has been reported 
that depletion of sec61 or the use of ExoA did not have any impact 
in cross-presentation of an HLA-A2-restricted epitope by human 
DC differentiated from monocytes (203). Another member of the 
ERAD machinery related to cytosolic export of antigens during 
cross-presentation is the soluble AAA ATPase p97, which is 
thought to provide the required energy for the passage of proteins 
through ER membranes (204). The addition of purified recom-
binant p97, but not a dominant negative form of the protein, is 
enough to promote the export of proteins from purified lucif-
erase-loaded phagosomes even in the absence of other cytosolic 
factors (205). In functional terms, cells expressing a dominant 
negative form of p97 show a decrease in cross-presentation of 
soluble OVA (205). In vivo evidence of ER-associated process for 
antigen transport to the cytosol is provided by a mouse knockout 
for the heat shock protein 90 (HSP90) (206). HSP90 is a chaper-
one associated with the ERAD complex on the cytosolic side of 
the ER, and its knockdown in the DC-like cell line KG-1 impairs 
the refolding of proteins that have gained access to the cytosol 
(207). Soluble cytochrome c does not induce apoptosis in BMDCs 
from HSP90α-null indicating that HSP90 might participate to the 
cytosolic export of soluble proteins (208). Importantly, in  vivo 
apoptosis of splenic cDC1s induced by cytochrome c injection is 
also impaired in HSP90α-null mice, and cross-priming of splenic 
CD8+ T cells isolated from HSP90α-null mice after immunization 
with OVA-coated splenocytes is reduced (206).
Finally, mice lacking the ɣ-interferon-inducible lysosomal 
thiol reductase (GILT)  –  which is present in phagosomes and 
lysosomes – are deficient in their ability to cross-present gB, an 
HSV-1 glycoprotein that contains five disulfide bonds. As the 
cytosolic export of ERAD substrates containing disulfide bonds 
requires their prior reduction and unfolding, it is feasible that 
GILT regulates cross-presentation by facilitating an ERAD-
dependent transport of reduced antigens carrying disulfide 
bonds to the cytosol (209).
Of note, soluble antigens might also enter ERAD after having 
reached ER lumen by retrograde transport. This possibility is 
supported by in vitro studies reporting that a significant part of 
soluble OVA captured by moDCs actually reaches the ER lumen 
(210). Whether this is relevant for cell-associated antigens in 
cDCs remains to be established.
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In summary, despite the incomplete understanding of the 
cellular machinery required for cytosolic transport of endocytic 
antigens, there is evidence indicating that cDCs have developed 
specific features to enhance the efficiency of cytosolic export.
where Does MHC Class i Loading Occur 
During Cross-Presentation?
Early experiments showing that cross-presentation could be 
inhibited by treatments like brefeldin A (149, 186), which blocks 
the anterograde transport of ER-synthesized proteins through 
the secretory pathway, led to the initial idea that MHC-I loading 
took place at the ER. Subsequent studies have demonstrated a 
fusion between the ER membrane and the phagosome at an early 
phagocytic step, indicating that the ER can provide a source of 
membrane to the phagosme for the loading of MHC-I molecules 
(196). Consistent with this idea, TAP, tapasin, calreticulin, Erp57, 
and the heavy chain of MHC class I are detected in purified early 
phagosomes from DCs (197). More importantly, MHC-I loaded 
with peptide was more abundant in phagosomes containing 
OVA-coupled beads, which indicates a direct loading of MHC-I 
molecules at the phagosome rather than a delivery of MHC-I 
loaded molecules to the phagosome (197). Depletion of sec22b 
impairs the recruitment of ER proteins like TAP2, tapasin, and 
calreticulin to the phagosome and cross-presentation by moDCs 
(199). These results point to a role of sec22 in the recruitment 
of essential components of the peptide-loading complex to the 
phagosome, the delivery of MHC-I to the phagosome does not 
seem to be altered by the depletion of sec22b. This is consistent 
with the intracellular localization of MHC-I, which at steady state 
is mainly found at the plasma membrane and the recycling endo-
some but not at the ER (211). Therefore, it is feasible to consider 
that part of the MHC-I loading might also occur at an endosomal 
compartment. Supporting this idea, the Jefferies laboratory has 
shown that murine DCs expressing mutated forms of the MHC-I 
receptor lacking a tyrosine residue of its cytoplasmic domain have 
an impaired MHC-I distribution and a reduction/loss in cross-
presentation (212). The MHC-II chaperone might also be involved 
in an interaction with MHC-I and participates in the diversion of 
MHC-I toward endo-lysosomes (213). Whereas these results indi-
cate that the loading of MHC-I molecules also occurs at the late 
endosome/lysosome, it is less clear if MHC-I loading at the endo-
somal compartment requires components of the cytosolic pathway 
or exclusively relies in the vacuolar pathway. For further discussion 
on MHC-I trafficking and its relevance to cross-presentation, see 
the accompanying review by Adiko Assi et al. in this issue.
Kurts and Burgdorf have reported that TLR engagement stim-
ulates the recruitment of TAP and MHC-I to a mannose receptor-
containing population of early endosomes in murine moDCs, 
specifically. Specific inhibition of TAP in early endosomes using 
the viral TAP luminal inhibitor US6 fused to transferrin inhibited 
cross-presentation but not direct presentation (which relies on 
ER-associated TAP) (176). By contrast, a recent study describes 
ERGIC-derived and sec22b-dependent TAP recruitment to 
bacteria-containing phagosomes as a constitutive mechanism, 
independent of TLR activation (214). Alternatively, TLR activa-
tion regulates cross-presentation by promoting the transport of 
MHC-I molecules from a recycling endosomal compartment to 
the phagosome. This process is mediated by the phosphorylation 
of SNAP23 via Myd88-dependent IKK2 activation and requires 
the recycling endosome GTPase Rab11 (214). Interestingly, 
mouse and human cDC1 cells express higher levels of Rab11, as 
compared to their cDC2s counterparts (71), a feature that needs 
further exploration to determine whether it is relevant or not for 
the cross-presentation of cell-associated antigens.
However, there is no doubt that cross-presentation can take 
place in steady state, non-activated DCs. Accordingly, DCs 
deficient in TLR signaling (Myd88−/−/TRIF−/−) do not show any 
major defects in cross-presentation (215). However, TLR3 is 
selectively associated with both mouse and human cDC1s (37, 
47–49, 53). Accordingly, synthetic or viral agonists of the TLR3–
TRIF pathway in particular, when associated with dead cells 
provide a strong co-activation stimulus for the cross-priming 
of CD8+ T cells specific for cell-associated antigens (89, 216). A 
more recent paper has shown that in Batf3−/− lacking the CD103+ 
DCs CTL responses upon soluble OVA immunization and TLR3 
stimulation by polyIC are impaired. Interestingly, the dependence 
on TLR3 expression was exclusive of cell-associated antigen, as 
in TLR3−/− mice immunization with soluble OVA together with 
polyIC induced strong CTL responses depending on the dsRNA 
sensors MDA5/RIG-I (217).
It is rather difficult to disentangle the effects of TLR signaling 
on DC activation from the ones associated with antigen cross-
presentation by MHC class I. Nevertheless, multiple studies sug-
gest that TLR signaling, especially by intracellular TLRs (TLR3, 
7, and 9) improve cross-presentation (218, 219).
TLR3, 7, and 9 rely on the Unc93b for their transport from ER 
to the endocytic pathway independently from the Golgi appara-
tus (220–222). Interestingly, DCs from Unc93b mutant mice were 
initially reported to be deficient in their ability to perform cross-
presentation of cell-associated antigens (220). These findings have 
been challenged by a recent study that did not identify differences 
between wild-type and Unc93b-mutated DCs (223). Further 
quantitative studies might clarify this point but it is tempting to 
speculate that Unc93b might have a TLR-independent effect on 
the trafficking enabling cross-presentation, perhaps by regulat-
ing the transport of the peptide-loading complex outside of the 
secretory pathway.
Concluding Remarks
The physiological relevance of the cross-presentation of cell-asso-
ciated antigens is well acknowledged. Whether cross-presentation 
by MHC-I is a passive consequence of limited phagolysosomal 
digestion of dead cell bodies or something more specifically 
regulated remains to be understood. The identification of the 
molecular machineries controlling cross-presentation in cDCs 
should shed some light on this process.
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